Intralesional rituximab in the treatment of indolent primary cutaneous B-cell lymphomas: an epidemiological observational multicentre study. The Spanish Working Group on Cutaneous Lymphoma

Peñate, Yeray; Hernández‐Machín, Buenaventura; Pérez‐Méndez, Lina; Santiago, Felicidade; Rosales, B.; Servitje, Octavio; Estrach, Teresa; Fernández‐Guarino, M.; Calzado, L.; Acebo, Elvira; Gallardo, Fernando; Salar, Antonio; Izu, R.; Ortiz‐Romero, Pablo L.; Pujol, Ramón M.; Fernández-de-Misa, Ricardo

doi:10.1111/j.1365-2133.2012.10902.x

Cited by 67 publications

(56 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In selected cases with positive serology for chronic Borrelia burgdorferi infection, oral antibiotics (cephalosporins or tetracyclines classes) can be tried. As second line treatment in these cases, intralesional (IL) IFN-alpha (3 mil UI three times/week), IL rituximab (CR 71%),[45] and IL corticosteroid are all viable options.…”

Section: Primary Cutaneous Marginal Zone Lymphomamentioning

confidence: 99%

A literature revision in primary cutaneous B-cell lymphoma

et al. 2017

View full text Add to dashboard Cite

The term “Primary Cutaneous B-Cell Lymphoma” (PCBCL) comprehends a variety of lymphoproliferative disorders characterized by a clonal proliferation of B-cells primarily involving the skin. The absence of evident extra-cutaneous disease must be confirmed after six-month follow-up in order to exclude a nodal non-Hodgkin's lymphoma (NHL) with secondary cutaneous involvement, which may have a completely different clinical behavior and prognosis. In this article, we have summarized the clinico-pathological features of main types of PCBCL and we outline the guidelines for management based on a review of the available literature.

show abstract

Section: Primary Cutaneous Marginal Zone Lymphomamentioning

confidence: 99%

A literature revision in primary cutaneous B-cell lymphoma

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Thus, it should be considered a useful alternative in patients with recurrent lesions and in whom the sequelae of radiotherapy or surgery would be significant. [31]…”

Section: Primary Cutaneous B-cell Lymphomasmentioning

confidence: 99%

Novel applications of Rituximab in dermatological disorders

Bhandari

Pai

2014

Indian Dermatol Online J

View full text Add to dashboard Cite

Rituximab is a monoclonal therapeutic anti-CD20 antibody that has been approved for use in lymphoma and rheumatoid arthritis. Over the past decade several reports based on case series and observational studies have recorded the benefits of rituximab in particular groups of dermatological patients. Off-label use of rituximab in many dermatological indications is not uncommon in many countries in the world. This article reviews the available data that may be of use to the practicing dermatologist. Because of its potential complications, paucity of clinical data, and cost considerations, rituximab is favoured only when standard systemic therapies fail or corticosteroids are absolutely contraindicated. Further research is required in this field.

show abstract

“…For example, intralesional rituximab has been shown to be a well-tolerated and effective treatment for Primary cutaneous marginal zone B-cell lymphoma. 10 To our knowledge, this is the first reportof SCMZL presenting solely with localized lipoatrophy. A case of SCMZL presenting with generalized lipoatrophy has been reported in which an 81-year-old woman who presented with numerous atrophic plaques on her trunk and proximal extremities.…”

Section: Case Reportmentioning

confidence: 99%

Secondary cutaneous marginal zone B-cell lymphoma presenting as lipoatrophy in a patient with hepatitis C

Beck¹,

Paul²,

Sawardekar³

et al. 2014

J Dermatol Case Rep

View full text Add to dashboard Cite

Background: Hepatitis C viral infection is a significant public health problem; 170 million persons are infected worldwide and the prevalence in the southern part of the United States exceeds two percent. Extrahepatic manifestations of hepatitis C viral infection are common; notably, 15-20% of patients will develop cutaneous manifestations of their disease. There are numerous dermatologic diseases associated with hepatitis C infection, including lichen planus, leukocytoclasticvasculitis, and porphyria cutaneatarda.

show abstract

Intralesional rituximab in the treatment of indolent primary cutaneous B-cell lymphomas: an epidemiological observational multicentre study. The Spanish Working Group on Cutaneous Lymphoma

Abstract: Intralesional rituximab is a well-tolerated and effective treatment for FCL and MZL PCBL. It should be considered a useful alternative in patients with recurrent lesions and in which the sequelae of radiotherapy or surgery would be significant.

Cited by 67 publications

References 12 publications

A literature revision in primary cutaneous B-cell lymphoma

A literature revision in primary cutaneous B-cell lymphoma

Novel applications of Rituximab in dermatological disorders

Secondary cutaneous marginal zone B-cell lymphoma presenting as lipoatrophy in a patient with hepatitis C

Contact Info

Product

Resources

About